<DOC>
	<DOC>NCT01516892</DOC>
	<brief_summary>This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.</brief_summary>
	<brief_title>A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Diagnosis of chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) Diagnosis of myasthenia gravis, EatonLambert Syndrome, or amyotrophic lateral sclerosis Headache attributed to another disorder Infection or skin disorder at injection sites Previous treatment with botulinum toxin of any serotype for any reason Anticipated need for botulinum toxin of any type for any reason during the course of the study Previous participation in any botulinum toxin clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>